Delveinsight

SEPTEMBER 23, 2021

The biotech has evolved a T-cell receptor-like antibody to damage a selected immune checkpoint in oncology. 858 Therapeutics closes USD 60 Million series A round to drug RNA modulation. Now, they are ready for their next venture, which is launching RNA biotech 858 Therapeutics with a USD 60 million Series A fundraising.

RNA 61

RNA Gene Therapy Gene Protein 61

Pharmaceutical Technology

FEBRUARY 1, 2023

Since the FDA approved AstraZeneca’s monoclonal antibody therapy Synagis (palivizumab) 25 years ago, drug development successes for RSV have been few and far between. The two types of candidates currently in the pipeline can be categorised as monoclonal antibodies and vaccines.

Vaccine 162

Vaccine Vaccination Antibody Development 162

Worldwide Clinical Trials

MAY 30, 2024

This research community is exploring diverse therapeutic avenues and creative thinking, including gene therapies, cell therapies, immunotherapies, novel drug candidates, and the repurposing of drugs from other indications.

Gene 204

Gene Clinical Trials Clinical Trials Gene Therapy 204

Pharmaceutical Technology

DECEMBER 9, 2022

The move is particularly timely given the significant growth expected in global sales of cell and gene therapies. Beyond our expertise in small molecules, we have built a solid reputation with biopharmaceutical companies for the characterisation and analysis of monoclonal antibodies, therapeutic proteins and biosimilars.

Development 130

Development Production Manufacturing Vaccine 130

XTalks

NOVEMBER 30, 2023

Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable. These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV. percent in the placebo group.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Gene 111

pharmaphorum

AUGUST 22, 2022

” For example, Torrance recently met with an expert from the Broad Institute who has been looking into gene therapies and says gene therapy can completely change how drugs are built. The Fund has owned Genmab , a Danish biotechnology company that creates antibody therapies for cancer, for 12 years.

Gene Therapy 102

Gene Therapy Antibody Gene Medicine 102

pharmaphorum

MARCH 9, 2022

Sanofi and Sobi’s haemophilia partnership has been under competitive pressure from new therapies like Roche’s antibody Hemlibra, so the two companies are hoping a new long-acting drug candidate can revitalise the franchise.

Protein 98

Protein Gene Therapy Sales Regulation 98

Delveinsight

AUGUST 5, 2021

The acquisition is the recent sign that large pharmaceutical companies view messenger RNA, which BioNTech and Moderna utilized to develop the COVID-19 vaccines now cleared for use in dozens of countries, as a crucial drug-making platform. Fibroblasts are part of the platform fueling cell-based gene therapy biotech Castle Creek.

Vaccine 98

Vaccine Vaccination Gene Therapy Development 98

Roots Analysis

MAY 21, 2024

Several LNP-based therapies are currently being evaluated in the clinical trials; majority of these are conducted for treating breast cancer, ovarian cancer and lung cancer. In addition, these can be modified with ligands in order to improve the specificity and selectivity of the gene therapy and reduce off-target effects.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

XTalks

JUNE 4, 2024

Today, there’s been a shift towards more complex, large molecules or biologics like monoclonal antibodies, antibody-drug conjugates (ADCs) and advanced therapies like RNA-based treatments and cell and gene therapies.

Clinical Development 110

Clinical Development Development Clinical Trials Clinical Trials 110

The Pharma Data

DECEMBER 27, 2020

Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study of monoclonal antibody VIR-7831 for hospitalized adults with COVID-19. Galidesivir is a broad-spectrum antiviral, an adenosine nucleoside analog that blocks viral RNA polymerase. Here’s a look. COVID-19-Related. Non-COVID-19-Related.

Trials 52

Trials Antibody Gene Therapy Gene 52

pharmaphorum

OCTOBER 12, 2022

Genomic medicine is a rapidly growing space in which researchers use the information in a person’s genes to identify and administer medical treatment.”. The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells. and France to accelerate the development of genomic therapies.

Genome 105

Genome Genomics Medicine Development 105

pharmaphorum

JULY 21, 2021

It is a small interfering RNA (siRNA) therapy that works by inhibiting PCSK9 – the same target as Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Repatha (alirocumab) – but is dosed only twice a year rather than every month. Its innovative medicines division climbed 15% to $10.6 Leukaemia dug asciminab filed.

Sales 52

Sales Gene Therapy RNA Production 52

The Pharma Data

JANUARY 10, 2021

CERC-002 is a human anti-LIGHT monoclonal antibody. FBX-101 is a first-in-human AAV gene therapy. Krabbe disease is a rare and fatal pediatric leukodystrophy caused by mutations in the galactosylceramidase (GALC) gene. The drug is an RNA interference (RNAi) therapeutic. Most Read Today. Source link.

Gene Therapy 52

Gene Therapy Trials Gene Clinical Trials 52

pharmaphorum

JULY 11, 2022

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at the International Society on Thrombosis and Haemostasis (ISTH) congress over the weekend.

Engineer 52

Engineer Gene Therapy Sales Drugs 52

WCG Clinical

MAY 28, 2024

B cells are needed in order to mount new antibody responses against vaccines and infections, so a lack of B cells can potentially result in immune deficiency and an increased risk of infection. If circulating antibody levels become too low, they may be supplemented with immunoglobulin therapy.

In-Vivo 40

In-Vivo Clinical Trials Clinical Trials FDA Approval 40

pharmaphorum

APRIL 28, 2022

These included setting their sights beyond haemophilia and growth hormone deficiencies into the wider, but still focused, spaces of red blood and endocrine disorders; a commercial enhancement program helping the company to launch medicines faster and with more impact; and a number of acquisitions that have given the company footholds in new treatment (..)

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

XTalks

AUGUST 2, 2023

2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. Meanwhile, BioMarin’s gene therapy Roctavian is approved by the FDA for the treatment of hemophilia A. billion in 2022, a 32.44

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

AUGUST 30, 2022

We know that a lot of different pathologies, especially as we’ve entered the era of molecular medicine and gene therapies, cause many of the same symptoms and work through final common pathways. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets? Next Steps for Targeted CNS Delivery.

Trials 83

Trials Drug Delivery Drugs Gene 83

XTalks

MAY 29, 2024

In its acquisitions, J&J also acquired antibody-drug conjugate (ADC) developer Ambryx and cardiac med tech Laminar along with more than 50 smaller, early-stage licensing deals and partnerships. billion to acquire Telavant for an anti-TL1A antibody, an inflammatory bowel disease candidate ready for Phase III trials.

Pharma Companies 52

Pharma Companies Sales FDA Approval Vaccine 52

XTalks

DECEMBER 24, 2020

From rare disease drug approvals to treatments involving immunotherapies and gene therapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. Antibody drugs were also developed as targeted COVID-19 treatments.

Life Science 111

Life Science Vaccine Vaccination Gene 111

Pharmaceutical Technology

APRIL 27, 2023

GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6 Almost 20 years later, the benefits of SUT are well recognised in the manufacture of monoclonal antibodies and biopharmaceutical manufacturing in general. billion by 2028. This is what SUT offers.”

Manufacturing 130

Manufacturing RNA Contamination Vaccination 130

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. Conde says the use of nanoparticle delivery for gene therapies has become more common over recent years. Langer, now a David H.

Drug Delivery 147

Drug Delivery Vaccine Vaccination Research 147

Drug Discovery World podcast

DECEMBER 2, 2024

This week’s leading news stories all feature early-stage clinical trials, including a short interfering RNA for cardiovascular disease, a new type of drug for type 2 diabetes, a gene therapy for Duchenne muscular dystrophy, a T cell therapy for hepatitis B, and a monoclonal antibody to prevent respiratory syncytial virus.

Gene Therapy 52

Gene Therapy RNA Clinical Trials Clinical Trials 52